SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025
Rhea-AI Summary
SS Innovations (Nasdaq: SSII) reported preliminary unaudited results for Q4 and full-year 2025 showing significant unit and revenue growth. Q4 2025 revenue is estimated at $15.0 million, up 85% from $8.1 million a year earlier, with 37 SSi Mantra installations in the quarter, up 68% year-over-year. Full-year 2025 revenue is estimated at $43.0 million, up 108% from $20.6 million in 2024, and 103 SSi Mantra installations for the year, up 119%.
The cumulative installed base reached 168 systems at year-end 2025. Management said FDA 510(k) review and EU CE marking are anticipated in the first half of 2026. Results are preliminary, unaudited and subject to final quarter-end procedures and change.
Positive
- Q4 revenue estimated at $15.0M (+85% YoY)
- Full-year 2025 revenue estimated at $43.0M (+108% YoY)
- 103 SSi Mantra installations in 2025 (+119% YoY)
- Cumulative installed base 168 systems at 12/31/2025 (+158% YoY)
Negative
- Preliminary results are unaudited and subject to change
- Regulatory clearances (FDA 510(k) and EU CE) remain pending in H1 2026
News Market Reaction
On the day this news was published, SSII gained 10.84%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.1% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $115M to the company's valuation, bringing the market cap to $1.17B at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SSII fell 3.08% pre-announcement while key device peers were mixed: IART -3.1%, BBNX -11.79%, ESTA -7.12%, NVCR -5.53%, but AHCO +1.34%. With no peers in the momentum scanner and split moves, trading appeared more stock-specific than a clear sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Leadership change | Neutral | -1.4% | Appointed new Global COO and CFO to support growth strategy. |
| Jan 06 | Product expansion | Positive | +6.5% | Introduced five new 5mm instruments to expand robotic use cases. |
| Dec 08 | Regulatory filing | Positive | +0.6% | Submitted 510(k) to FDA and outlined EU CE marking plans. |
| Nov 06 | Technology milestone | Positive | -2.3% | Announced first telesurgery using the Tele Surgeon Console. |
| Oct 28 | Earnings update | Negative | -0.9% | Reported strong Q3 growth alongside ongoing losses and going-concern risk. |
Recent operational and technology milestones often saw modest or mixed price reactions, with occasional positive spikes on product expansion news.
Over the last few months, SS Innovations has focused on expanding its SSi Mantra platform and global readiness. Q3 2025 results on Oct 28 showed strong revenue growth but ongoing losses and going-concern language. Subsequent news highlighted a first telesurgery milestone on Nov 6 and submission of a 510(k) to the FDA on Dec 5. Early January 2026 updates included new 5mm instruments and a leadership change. Today’s preliminary Q4 and full-year 2025 revenue figures build directly on that growth and adoption trajectory.
Market Pulse Summary
The stock surged +10.8% in the session following this news. A strong positive reaction aligns with the company’s reported growth, with preliminary Q4 2025 revenue of $15.0M and full-year 2025 revenue of $43.0M showing sharp year-over-year increases. However, prior filings noted ongoing losses and going‑concern risks, which could cap enthusiasm once the full results are released. Historical news often produced only modest follow-through, so sustainability would depend on confirmed profitability trends and progress on the 510(k) and EU CE marking timelines.
Key Terms
510(k) premarket notification regulatory
u.s. food and drug administration regulatory
ce marking regulatory
gaap financial
AI-generated analysis. Not financial advice.
Anticipated strong revenue growth driven by higher unit sales of SSi Mantra surgical robotic system
FORT LAUDERDALE, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other select operating metrics for the three and twelve months ended December 31, 2025.
For the fourth quarter of 2025, the Company expects to report:
- Revenue of approximately
$15.0 million , up85% from revenue of$8.1 million in the fourth quarter of 2024. - SSi Mantra installations of 37, up
68% from 22 installations in the fourth quarter of 2024.
For the full year 2025, the Company expects to report:
- Revenue of approximately
$43.0 million , up108% from revenue of$20.6 million in 2024. - SSi Mantra installations of 103, up
119% from 47 installations in 2024.
The SSi Mantra cumulative installed base totaled 168 as of December 31, 2025, up
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We expect to report strong fourth quarter revenue growth, driven by higher unit sales of our advanced, cost-effective SSi Mantra surgical robotic system in India and abroad. We are committed to democratizing excellence in surgical care on a global scale, including in the United States and Europe. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra in the first half of 2026. We also continue along the pathway towards a European Union CE marking certification for the SSi Mantra, which we believe we can obtain in the first half of 2026. We look forward to providing additional financial details when we release our fourth quarter financial results in the latter part of February.”
The Company expects to report its fourth quarter and full year 2025 financial results before the end of February.
The estimated financial and operating results in this press release are preliminary, unaudited and subject to completion, and may change as a result of management's continued review. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. As a result, investors should exercise caution in relying on this information and should not draw any inferences from this information. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and reviewed by our independent registered public accounting firm.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations, including, but not limited to, statements regarding the Company’s fourth quarter 2025 and full year 2025 preliminary results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations and other statement that are predictive in nature. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
FAQ
What revenue did SS Innovations (SSII) report for Q4 2025?
How many SSi Mantra installations did SSII record in 2025?
When does SS Innovations expect FDA and CE decisions for SSi Mantra?
Are SS Innovations' Q4 and full-year 2025 results final?
How large is SS Innovations' installed base as of December 31, 2025?
